133 related articles for article (PubMed ID: 1990756)
1. The effect of quinidine and mexiletine on the adaptation of ventricular refractoriness to an increase in rate.
Rosenheck S; Schmaltz S; Kadish AH; Summitt J; Morady F
Am Heart J; 1991 Feb; 121(2 Pt 1):512-7. PubMed ID: 1990756
[TBL] [Abstract][Full Text] [Related]
2. The effect of rate on prolongation of ventricular refractoriness by quinidine in humans.
Rosenheck S; Sousa J; Calkins H; Kadish AH; Morady F
Pacing Clin Electrophysiol; 1990 Nov; 13(11 Pt 1):1379-84. PubMed ID: 1701891
[TBL] [Abstract][Full Text] [Related]
3. The maximum effect of an increase in rate on human ventricular refractoriness.
Morady F; Kadish AH; Toivonen LK; Kushner JA; Schmaltz S
Pacing Clin Electrophysiol; 1988 Dec; 11(12):2223-34. PubMed ID: 2463610
[TBL] [Abstract][Full Text] [Related]
4. Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo.
Costard-Jäckle A; Franz MR
J Pharmacol Exp Ther; 1989 Oct; 251(1):39-46. PubMed ID: 2795468
[TBL] [Abstract][Full Text] [Related]
5. Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans.
Duff HJ; Mitchell LB; Manyari D; Wyse DG
J Am Coll Cardiol; 1987 Nov; 10(5):1149-56. PubMed ID: 3668109
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of oral quinidine-mexiletine combination therapy for sustained ventricular tachyarrhythmias as assessed by programmed electrical stimulation when quinidine monotherapy has failed.
Bonavita GJ; Pires LA; Wagshal AB; Cuello C; Mittleman RS; Greene TO; Huang SK
Am Heart J; 1994 Apr; 127(4 Pt 1):847-51. PubMed ID: 8154423
[TBL] [Abstract][Full Text] [Related]
7. Frequency-dependent effect of quinidine, mexiletine, and their combination on postrepolarization refractoriness in vivo.
Costard-Jaeckle A; Liem LB; Franz MR
J Cardiovasc Pharmacol; 1989 Dec; 14(6):810-7. PubMed ID: 2481766
[TBL] [Abstract][Full Text] [Related]
8. Electropharmacologic synergism with mexiletine and quinidine.
Duff HJ; Kolodgie FD; Roden DM; Woosley RL
J Cardiovasc Pharmacol; 1986; 8(4):840-6. PubMed ID: 2427827
[TBL] [Abstract][Full Text] [Related]
9. Effect of sudden rate acceleration on the human His-Purkinje system: adaptation of refractoriness in a dampened oscillatory pattern.
Tchou PJ; Lehmann MH; Dongas J; Mahmud R; Denker ST; Akhtar M
Circulation; 1986 May; 73(5):920-9. PubMed ID: 3698237
[TBL] [Abstract][Full Text] [Related]
10. Role of quinidine in the mexiletine-quinidine interaction: electrophysiologic correlates of enhanced antiarrhythmic efficacy.
Duff HJ; Rahmberg M; Sheldon RS
J Cardiovasc Pharmacol; 1990 Nov; 16(5):685-92. PubMed ID: 1703588
[TBL] [Abstract][Full Text] [Related]
11. Mexiletine-quinidine in isolated hearts: an interaction involving the sodium channel.
Duff HJ; Cannon NJ; Sheldon RS
Cardiovasc Res; 1989 Jul; 23(7):584-92. PubMed ID: 2557155
[TBL] [Abstract][Full Text] [Related]
12. Comparative hemodynamic effects of mexiletine and quinidine in patients with severe left ventricular dysfunction.
Gottlieb SS; Weinberg M
Am Heart J; 1991 Nov; 122(5):1368-74. PubMed ID: 1951002
[TBL] [Abstract][Full Text] [Related]
13. Is the adaptation of right ventricular refractoriness to an abrupt increase in heart rate impaired in chronic heart failure?
Denardo SJ; Stevenson WG
Am Heart J; 1989 Mar; 117(3):585-9. PubMed ID: 2465681
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of quinidine's electrophysiologic effects by epinephrine in patients with ventricular tachycardia.
Morady F; Kou WH; Kadish AH; Nelson SD; Toivonen LK; Kushner JA; Schmaltz S; de Buitleir M
J Am Coll Cardiol; 1988 Aug; 12(2):388-94. PubMed ID: 3392332
[TBL] [Abstract][Full Text] [Related]
15. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
Kus T; Costi P; Dubuc M; Shenasa M
Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
[TBL] [Abstract][Full Text] [Related]
16. Mexiletine/quinidine combination therapy: electrophysiologic correlates of anti-arrhythmic efficacy.
Duff HJ; Mitchell LB; Wyse DG; Gillis AM; Sheldon RS
Clin Invest Med; 1991 Oct; 14(5):476-83. PubMed ID: 1660369
[TBL] [Abstract][Full Text] [Related]
17. Effects of quinidine on ventricular repolarization.
Brugada J; Sassine A; Escande D; Masse C; Puech P
Eur Heart J; 1987 Dec; 8(12):1340-5. PubMed ID: 3436332
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral mexiletine on left and right ventricular function.
Stein J; Podrid P; Lown B
Am J Cardiol; 1984 Sep; 54(6):575-8. PubMed ID: 6475776
[TBL] [Abstract][Full Text] [Related]
19. Effect of mexiletine on monophasic action potentials recorded from the right ventricle in man.
Harper RW; Olsson SB; Varnauskas E
Cardiovasc Res; 1979 Jun; 13(6):303-10. PubMed ID: 476751
[TBL] [Abstract][Full Text] [Related]
20. Comparative electropharmacology of mexiletine, lidocaine and quinidine in a canine Purkinje fiber model.
Burke GH; Loukides JE; Berman ND
J Pharmacol Exp Ther; 1986 Apr; 237(1):232-6. PubMed ID: 3958966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
